Taysha Gene Therapies Q4 Earnings Call Highlights

Management also emphasized tolerability across studies to date. Nolan said both high- and low-dose TSHA-102 have continued to be generally well-tolerated, with no treatment-related serious adverse events or dose-limiting toxicities observed in patients treated in the REVEAL Phase I/II and REVEAL pivotal trials as of the March 2026 data cutoff.The company initiated the REVEAL pivotal trial in the fourth quarter of 2025 with dosing of the first patient. Nolan said multiple patients have now been dosed, enroll ...